HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Impact of HLA class I functional divergence on HIV control.

Abstract
Heterozygosity of Human leukocyte antigen (HLA) class I genes is linked to beneficial outcomes after HIV infection, presumably through greater breadth of HIV epitope presentation and cytotoxic T cell response. Distinct allotype pairs, however, differ in the extent to which they bind shared sets of peptides. We developed a functional divergence metric that measures pairwise complementarity of allotype-associated peptide binding profiles. Greater functional divergence for pairs of HLA-A and/or HLA-B allotypes was associated with slower AIDS progression and independently with enhanced viral load control. The metric predicts immune breadth at the peptide level rather than gene level and redefines HLA heterozygosity as a continuum differentially affecting disease outcome. Functional divergence may affect response to additional infections, vaccination, immunotherapy, and other diseases where HLA heterozygote advantage occurs.
AuthorsMathias Viard, Colm O'hUigin, Yuko Yuki, Arman A Bashirova, David R Collins, Jonathan M Urbach, Steven Wolinsky, Susan Buchbinder, Gregory D Kirk, James J Goedert, Nelson L Michael, David W Haas, Steven G Deeks, Bruce D Walker, Xu Yu, Mary Carrington
JournalScience (New York, N.Y.) (Science) Vol. 383 Issue 6680 Pg. 319-325 (01 19 2024) ISSN: 1095-9203 [Electronic] United States
PMID38236978 (Publication Type: Journal Article)
Chemical References
  • HLA-B Antigens
  • Peptides
Topics
  • Humans
  • Alleles
  • Disease Progression
  • Heterozygote
  • HIV Infections (genetics, pathology)
  • HLA-B Antigens (genetics)
  • Peptides (genetics, immunology)
  • Male
  • Female
  • Young Adult
  • Adult
  • Middle Aged
  • Aged

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: